Solasia Pharma K.K. (4597.T)
JPY 42.0
(2.44%)
JPY 42.0
(2.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 673 Million JPY | 42.58% |
| 2022 | 472 Million JPY | -15.26% |
| 2021 | 557 Million JPY | -73.76% |
| 2020 | 2.12 Billion JPY | 106.32% |
| 2019 | 1.02 Billion JPY | 60.53% |
| 2018 | 641 Million JPY | 43.55% |
| 2017 | 446.53 Million JPY | 64.45% |
| 2016 | 271.52 Million JPY | -91.3% |
| 2015 | 3.12 Billion JPY | 92.02% |
| 2014 | 1.62 Billion JPY | 116.61% |
| 2013 | 750.22 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 331 Million JPY | -62.22% |
| 2024 Q1 | 884 Million JPY | 31.35% |
| 2023 Q4 | 673 Million JPY | 84.38% |
| 2023 FY | 673 Million JPY | 42.58% |
| 2023 Q1 | 565 Million JPY | 19.7% |
| 2023 Q2 | 445 Million JPY | -21.24% |
| 2023 Q3 | 365 Million JPY | -17.98% |
| 2022 Q1 | 469 Million JPY | -15.8% |
| 2022 Q4 | 472 Million JPY | -57.55% |
| 2022 Q3 | 1.11 Billion JPY | 130.71% |
| 2022 Q2 | 482 Million JPY | 2.77% |
| 2022 FY | 472 Million JPY | -15.26% |
| 2021 Q2 | 1.16 Billion JPY | 0.87% |
| 2021 Q4 | 557 Million JPY | -26.42% |
| 2021 Q3 | 757 Million JPY | -34.74% |
| 2021 FY | 557 Million JPY | -73.76% |
| 2021 Q1 | 1.15 Billion JPY | -45.83% |
| 2020 FY | 2.12 Billion JPY | 106.32% |
| 2020 Q4 | 2.12 Billion JPY | -19.61% |
| 2020 Q3 | 2.64 Billion JPY | 442.3% |
| 2020 Q2 | 487 Million JPY | -35.15% |
| 2020 Q1 | 751 Million JPY | -27.02% |
| 2019 Q4 | 1.02 Billion JPY | 58.06% |
| 2019 FY | 1.02 Billion JPY | 60.53% |
| 2019 Q1 | 480 Million JPY | -25.12% |
| 2019 Q3 | 651 Million JPY | -4.96% |
| 2019 Q2 | 685 Million JPY | 42.71% |
| 2018 Q3 | 258 Million JPY | -30.83% |
| 2018 Q2 | 373 Million JPY | 56.07% |
| 2018 Q1 | 239 Million JPY | -46.48% |
| 2018 FY | 641 Million JPY | 43.55% |
| 2018 Q4 | 641 Million JPY | 148.45% |
| 2017 Q3 | 193.51 Million JPY | -18.32% |
| 2017 Q2 | 236.91 Million JPY | -8.38% |
| 2017 Q1 | 258.59 Million JPY | -4.76% |
| 2017 Q4 | 446.53 Million JPY | 130.75% |
| 2017 FY | 446.53 Million JPY | 64.45% |
| 2016 Q4 | 271.52 Million JPY | -91.19% |
| 2016 Q3 | 3.08 Billion JPY | 0.0% |
| 2016 FY | 271.52 Million JPY | -91.3% |
| 2015 FY | 3.12 Billion JPY | 92.02% |
| 2015 Q4 | 3.12 Billion JPY | 0.0% |
| 2014 FY | 1.62 Billion JPY | 116.61% |
| 2013 FY | 750.22 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 97.307% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.991% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.91% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 99.591% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | 80.177% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 98.43% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 97.585% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 99.864% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | 86.647% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 98.909% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 97.817% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 98.309% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 97.835% |
| Tsumura & Co. | 132.88 Billion JPY | 99.494% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 98.309% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 94.939% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 99.755% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 98.476% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 99.048% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 98.565% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 90.39% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 97.354% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 91.734% |
| MedRx Co., Ltd | 129 Million JPY | -421.705% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | 79.435% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -4.26% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 97.855% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 99.59% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | 33.455% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.872% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 90.32% |